mash semaglutide Wegovy (semaglutide 2.4 mg) approved in the US for the treatment of - Novo Nordisk Diabetes Dialogue: Semaglutide for MASH

Key Takeaways GLP-1 receptor agonists (GLP-1RAs) are a critical advancement in managing type 2 diabetes and obesity, offering significant benefits in blood sugar control and weight loss, but differ in their mechanisms of action, dosing schedules, and side effects

This issue can get better with time

Semaglutide is marketed under different brand names, such as Ozempic for type 2 diabetes management and Wegovy for weight loss

Cardiovascular disease remains the leading cause of morbidity and mortality in patients with diabetes, and interventions that can mitigate this risk are invaluable

Together, these effects help with blood sugar control and how the body uses and stores energy